DGX 250117 155.00C (DGX250117C155000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

DGX250117C155000

Watchlist

1.60
-0.40-20.00%

15min DelayClose Dec 26 16:00 ET

1.60High1.60Low

Intraday

5D
Daily

News

Mizuho Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Announces Target Price $177
Moomoo NewsDec 23 12:32 ET · Ratings
Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management
Yahoo FinanceDec 23 12:30 ET
Mizuho Adjusts Price Target on Quest Diagnostics to $177 From $174, Keeps Outperform Rating
MT NewswiresDec 23 05:56 ET · Ratings
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Kevin TraversDec 20 10:29 ET
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
BenzingaDec 19 13:38 ET
Is Quest Diagnostics (NYSE:DGX) Using Too Much Debt?
Simply Wall StDec 19 13:30 ET

Comments

ForeverBean

Jun 1 04:19

$Quest Diagnostics (DGX.US)$ PathAI + Invigorate + stable finance + qualified management team + decent PE.
Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.

Moomoo AI

Jan 11 05:10

Quest Diagnostics' consistent ROCE and increased capital employed over the past five years suggest steady reinvestment at good returns. This trend, reflected in the stock's strong performance, is expected to continue.

Returns On Capital At Quest Diagnostics (NYSE:DGX) Have Stalled

Moomoo AI

Jan 8 08:01

The acquisition aligns with Quest's strategy to grow through accretive outreach laboratory acquisitions and expands its ability to serve providers and patients in Ohio and Pennsylvania.

Press Release: Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System

Moomoo AI

Dec 20, 2023 06:39

The CEO of Quest Diagnostics, Jim Davis, believes Yuri Fesko's deep medical expertise and patient-care advocacy will greatly contribute to the company's strategic decisions. His appointment especially bolsters Quest's efforts to improve customer experiences via diagnostic innovations.

Press Release: Quest Diagnostics Names Yuri A. Fesko, M.D., Senior Vice President and Chief Medical Officer

Moomoo AI

Dec 6, 2023 04:43

Quest Diagnostics shows favorable metrics with robust reinvestment strategies. Significant earnings growth and an anticipated rise in future ROE, despite a higher payout ratio, hint at other growth factors.

Quest Diagnostics Incorporated's (NYSE:DGX) Stock Has Fared Decently: Is the Market Following Strong Financials?